Skip to main navigation Skip to search Skip to main content

A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis

  • Efstathios Kastritis
  • , Monique C Minnema
  • , Meletios-Athanasios A Dimopoulos
  • , Giampaolo Merlini
  • , Foteini Theodorakakou
  • , Despoina Fotiou
  • , Antoine Huart
  • , Giorgos Psarros
  • , Helen Vassalou
  • , Pieter Sonneveld
  • , Giovanni Palladini

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Treatment options for patients with immunoglobulin light chain (AL) amyloidosis and advanced cardiac involvement remain limited. The prospective phase 2 European Myeloma Network 22 trial included patients with previously untreated AL amyloidosis, measurable hematologic disease, and Mayo2004/European cardiac stage IIIB disease to receive daratumumab monotherapy at the standard dose and schedule for up to 2 years (28-day cycles); patients with inadequate response after 3 cycles could additionally receive weekly bortezomib and dexamethasone. The primary end point was 6-month overall survival (OS) rate. Of 40 patients enrolled, 10 (25.0%) received additional treatment with bortezomib and dexamethasone. The 6-month OS rate was 65% (95% confidence interval, 48.2-77.6), and median OS was 10.4 months. The best hematologic response rate (partial response or better) up to 6 months was 75% (very good partial response or better, 47.5%; complete response, 12.5%), with the median time to first and best hematologic response being 1 week and 2.3 months, respectively. Cardiac response rate at 6 months was 30%. Common serious adverse events were cardiac failure (25%), sudden cardiac death (10%), and acute kidney injury (7.5%). The patients’ quality of life remained stable throughout the trial treatment and observation. In patients with high-risk, advanced (stage IIIB) AL amyloidosis, daratumumab monotherapy was feasible and well tolerated, achieving rapid hematologic responses and associated with prolonged survival relative to historical cohorts. Cardiac response rates at 6 months were significant, considering advanced cardiac disease. These findings support daratumumab as the backbone of anticlonal therapy in advanced cardiac AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT04131309.

Original languageEnglish
Pages (from-to)1973-1983
JournalBlood
Volume148
Early online date15 Jun 2026
DOIs
Publication statusPublished - 15 Oct 2026

Fingerprint

Dive into the research topics of 'A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis'. Together they form a unique fingerprint.

Cite this